Indianapolis, IN (Apr. 16)—Ell Lilly plans to streamline a portion of its manufacturing operations in Indianapolis. The move would affect sites that manufacture the active pharmaceutical ingredients for Lilly’s insulin products “Humalog” and “Humulin” and for its osteoporosis drug “Forteo” (teriparatide recombinant human).
Eli Lilly says it “will align manufacturing capacity and engineering support services with the needs of the business,” for these products. The company will offer a voluntary exit program to employees and expects to reduce its Indianapolis employment by up to 500 people, predominantly in manufacturing but with a small portion in select areas of research and development.
The company plans to take an accounting charge in the second quarter of 2008. The amount of that charge has not yet been determined because it will depend upon the number of employees that choose to take the exit package.
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 22, 2008, Patricia Van Arnum, Eli Lilly to Streamline Manufacturing in Indianapolis